View Future GrowthAlmirall 過去の業績過去 基準チェック /56Almirallは、平均年間0.8%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間8.3% 6.3%収益成長率で 成長しています。 Almirallの自己資本利益率は3.1%であり、純利益率は4.1%です。主要情報0.76%収益成長率-5.01%EPS成長率Pharmaceuticals 業界の成長7.33%収益成長率6.33%株主資本利益率3.10%ネット・マージン4.14%次回の業績アップデート11 May 2026最近の業績更新Almirall, S.A. to Report Fiscal Year 2025 Results on Feb 23, 2026Nov 21+ 3 more updatesAlmirall, S.A. to Report Q1, 2025 Results on May 12, 2025Apr 14Almirall, S.A. to Report Fiscal Year 2024 Results on Feb 24, 2025Dec 20+ 2 more updatesThird quarter 2024 earnings released Nov 13Second quarter 2024 earnings released Jul 24First quarter 2024 earnings released May 15すべての更新を表示Recent updatesAlmirall, S.A., Annual General Meeting, May 08, 2026Apr 08Almirall S.A. Presents New Clinical and Real-World Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and AcneMar 28+ 1 more updateAlmirall Announces Positive Top-Line Results from Phase 3 Adorable-1 TrialMar 16Almirall, S.A. Provides Earnings Guidance for the Year 2026Feb 23Almirall Announces the Approval of Seysara in China for the Treatment of Moderate-To-Severe AcneJan 29Almirall Announces LumiNE, a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular EczemaJan 15Almirall, S.A. Presents R&D Pipeline Advances Supported by Sustained Growth and Leadership in Medical Dermatology At J.P. Morgan Healthcare ConferenceJan 14Almirall, S.A. to Report Fiscal Year 2025 Results on Feb 23, 2026Nov 21+ 3 more updatesAlmirall, S.A. Reiterates Earnings Guidance for the Full Year 2025Nov 10Almirall Advances Skin Science and Leads Innovation for Holistic Patient Care in Medical DermatologySep 19Almirall Presents Long-Term Results from First Real-World Dermatology Study Using WHO-5 Well-Being Index as Primary Endpoint in the Treatment of Psoriasis at EADV 2025Sep 18Almirall, S.A. Reiterates Earnings Guidance for Full Year 2025Jul 25Almirall, S.A. Approves Distribution of A DividendMay 12+ 1 more updateAlmirall, S.A. to Report Q1, 2025 Results on May 12, 2025Apr 14Almirall, S.A., Annual General Meeting, May 09, 2025Apr 01Almirall, S.A. Appoints Jon U. Garay Alonso as Member of the Management Board as of August 2025Mar 06Almirall, S.A. Provides Earnings Guidance for the Full Year 2025Feb 24Almirall, S.A. to Report Fiscal Year 2024 Results on Feb 24, 2025Dec 20+ 2 more updatesAlmirall Launches the Hive, Creating A Novel Collaborative Innovation Hub to Advance Life Sciences and HealthcareDec 04Third quarter 2024 earnings released Nov 13Almirall, S.A. Reiterates Earnings Guidance for Full Year 2024Nov 11Second quarter 2024 earnings released Jul 24Almirall, S.A. Reiterates Financial Guidance for Full Year 2024Jul 22Insufficient new directors Jul 01Almirall’s Ilumetri® (tildrakizumab) Restores and Maintains Wellbeing of Patients With Moderate-to-severe Plaque Psoriasis to the Levels of the General Population for up to 1 YearJun 29Almirall, S.A. Approves Distribution of DividendMay 15First quarter 2024 earnings released May 15Almirall, S.A. Provides Earnings Guidance for Full Year 2024May 15Almirall, S.A., Annual General Meeting, May 10, 2024Apr 09Full year 2023 earnings released: €0.20 loss per share (vs €0.024 profit in FY 2022) Feb 22Almirall, S.A. Provides Earnings Guidance for the Year 2024Feb 20Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune DiseasesDec 21Almirall, S.A. Receives European Commission Approval of EBGLYSS(R) (lebrikizumab) for Moderate to-Severe Atopic DermatitisNov 18Third quarter 2023 earnings released: EPS: €0.008 (vs €0.089 loss in 3Q 2022) Nov 13Almirall, S.A. Revises Earnings Guidance for the Year 2023Nov 11Almirall, S.A. to Report Fiscal Year 2023 Results on Feb 19, 2024Nov 10+ 3 more updatesAlmirall's Ilumetri (Tildrakizumab) Significantly Improves Wellbeing for Patients and Their Relatives in Moderate-To-Severe Plaque PsoriasisOct 13Now 20% undervalued Aug 29New minor risk - Shareholder dilution Jul 26Almirall, S.A. Reiterates Earnings Guidance for the Year 2023Jul 25Second quarter 2023 earnings released Jul 24Almirall Launches Nina, the First Series to Highlight the Major Impact of Psoriasis on Patient’s WellbeingJun 20Almirall, S.A. has completed a Follow-on Equity Offering in the amount of €199.999993 million.Jun 14First quarter 2023 earnings released May 11Almirall, S.A. Reiterates Earnings Guidance for the Year 2023May 08Full year 2022 earnings released: EPS: €0.02 (vs €0.23 loss in FY 2021) Feb 21Almirall, S.A., Annual General Meeting, May 05, 2023Feb 20+ 2 more updatesNow 20% undervalued Feb 04Now 20% undervalued after recent price drop Jan 11Almirall, S.A. to Report Nine Months, 2023 Results on Nov 16, 2023Nov 15+ 3 more updatesAlmirall, S.A. Maintains Earnings Guidance for the Full Year of 2022Nov 10Almirall, S.A. Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Lebrikizumab in Atopic DermatitisOct 28Almirall, S.A. Announces the 31st EADV Congress the Results from TRIBUTE, an Interventional Phase IV Clinical StudySep 15Almirall, S.A. Announces New Detailed Results from Phase 3 Monotherapy Studies in Atopic DermatitisSep 09Second quarter 2022 earnings released: EPS: €0.039 (vs €0.40 loss in 2Q 2021) Jul 26Almirall, S.A.(BME:ALM) dropped from Madrid Ibex 35 IndexJun 22Happify Health and Almirall, S.A. Go Live with Digital Solution to Support Psoriasis PatientsJun 14Almirall, S.A. Announces Topline Results from One-Year Analyses of the Efficacy and Safety of LebrikizumabJun 07Almirall, S.A. Announces Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic DermatitisApr 12Now 22% undervalued Mar 17Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 22Almirall, S.A. Announces Executive ChangesFeb 21+ 2 more updatesAlmirall launches innovative Wynzora® CAL/BDP cream in Europe for the treatment of mild to moderate plaque psoriasis in adults including scalpFeb 19Almirall Announces Results for Atopic Dermatitis in Third Phase 3 StudyDec 21Almirall, S.A. Launches Klisyri (Tirbanibulin) for the Treatment of Actinic Keratosis in EuropeSep 29Second quarter 2021 earnings released: €0.40 loss per share (vs €0.036 loss in 2Q 2020) Jul 27Almirall, S.A. Receives European Commission Approval of Klisyri® (Tirbanibulin)Jul 20Almirall and MC2 Therapeutics Announce Completion of Decentralized Procedure in Europe for the Topical Treatment of Mild to Moderate Psoriasis Vulgaris in AdultsJul 07Almirall Receives Positive CHMP Opinion for Klisyri®? (Tirbanibulin), an Innovative Topical Treatment for Actinic KeratosisMay 22First quarter 2021 earnings released: EPS €0.17 (vs €0.28 in 1Q 2020) May 14Full year 2020 earnings released: EPS €0.42 (vs €0.61 in FY 2019) Feb 25Revenue misses expectations Feb 25Almirall U.S. Launches Klisyri® (tirbanibulin), a New, Innovative Topical Treatment for Actinic KeratosisFeb 19Almirall and MC2 Therapeutics Enters a License, Collaboration and Commercialization Agreement for European Rights to Wynzora® Cream for treatment of Plaque PsoriasisFeb 18Almirall, S.A. Announces New Publication in the British Journal of Dermatology of ILUMETRIFeb 10Almirall, S.A. Announces Executive ChangesFeb 03+ 1 more updateAlmirall and Happify Health Enter into Strategic Partnership to Develop Evidence-Supported Digital Therapeutics Solutions for Psoriasis PatientsJan 29New 90-day high: €11.71 Jan 15Almirall, S.A. and Tyris Therapeutics Enter into Strategic Partnership to Develop Next Generation Gene TherapiesJan 08New 90-day high: €11.33 Dec 29Almirall, S.A. Announces U.S. Food and Drug Administration Approval of Klisyri® (Tirbanibulin), A New Innovative Topical Treatment for Actinic KeratosisDec 15収支内訳Almirall の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:E2Z 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費31 Dec 251,11546264030 Sep 251,085422561230 Jun 251,05421249031 Mar 251,02824246931 Dec 2499110235030 Sep 24953-452371230 Jun 24932-35220031 Mar 24915-39214331 Dec 23899-38209030 Sep 239077209730 Jun 23898-11201031 Mar 23882-8205331 Dec 228794202030 Sep 2286492072430 Jun 2285629197031 Mar 22843-50190831 Dec 21837-41188030 Sep 21814-22201-1030 Jun 21809-11185031 Mar 2179055188-831 Dec 2081474177030 Sep 2084963167-830 Jun 2087286188031 Mar 20926121188031 Dec 19911106189030 Sep 1985885227930 Jun 1988488182031 Mar 1978980209331 Dec 1881178183030 Sep 18714-111176-1030 Jun 18730-179196031 Mar 18687-293195-631 Dec 17677-304207030 Sep 17735-128215530 Jun 17755-78214031 Mar 1782173216531 Dec 1682275213030 Sep 167781622301030 Jun 16743154210031 Mar 16721111204231 Dec 15738132201030 Sep 15783479190-2830 Jun 158024882440質の高い収益: E2Zは 高品質の収益 を持っています。利益率の向上: E2Zの現在の純利益率 (4.1%)は、昨年(1%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: E2Zの収益は過去 5 年間で年間0.8%増加しました。成長の加速: E2Zの過去 1 年間の収益成長率 ( 354.9% ) は、5 年間の平均 ( 年間0.8%を上回っています。収益対業界: E2Zの過去 1 年間の収益成長率 ( 354.9% ) はPharmaceuticals業界12.5%を上回りました。株主資本利益率高いROE: E2Zの 自己資本利益率 ( 3.1% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/04 11:42終値2026/04/30 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Almirall, S.A. 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。26 アナリスト機関Luis ArredondoBanco de Sabadell. S.A.null nullBanco de Sabadell. S.A.Jaime EscribanoBanco Santander23 その他のアナリストを表示
Almirall S.A. Presents New Clinical and Real-World Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and AcneMar 28+ 1 more update
Almirall Announces the Approval of Seysara in China for the Treatment of Moderate-To-Severe AcneJan 29
Almirall Announces LumiNE, a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular EczemaJan 15
Almirall, S.A. Presents R&D Pipeline Advances Supported by Sustained Growth and Leadership in Medical Dermatology At J.P. Morgan Healthcare ConferenceJan 14
Almirall Advances Skin Science and Leads Innovation for Holistic Patient Care in Medical DermatologySep 19
Almirall Presents Long-Term Results from First Real-World Dermatology Study Using WHO-5 Well-Being Index as Primary Endpoint in the Treatment of Psoriasis at EADV 2025Sep 18
Almirall, S.A. Appoints Jon U. Garay Alonso as Member of the Management Board as of August 2025Mar 06
Almirall Launches the Hive, Creating A Novel Collaborative Innovation Hub to Advance Life Sciences and HealthcareDec 04
Almirall’s Ilumetri® (tildrakizumab) Restores and Maintains Wellbeing of Patients With Moderate-to-severe Plaque Psoriasis to the Levels of the General Population for up to 1 YearJun 29
Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune DiseasesDec 21
Almirall, S.A. Receives European Commission Approval of EBGLYSS(R) (lebrikizumab) for Moderate to-Severe Atopic DermatitisNov 18
Almirall's Ilumetri (Tildrakizumab) Significantly Improves Wellbeing for Patients and Their Relatives in Moderate-To-Severe Plaque PsoriasisOct 13
Almirall Launches Nina, the First Series to Highlight the Major Impact of Psoriasis on Patient’s WellbeingJun 20
Almirall, S.A. Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Lebrikizumab in Atopic DermatitisOct 28
Almirall, S.A. Announces the 31st EADV Congress the Results from TRIBUTE, an Interventional Phase IV Clinical StudySep 15
Almirall, S.A. Announces New Detailed Results from Phase 3 Monotherapy Studies in Atopic DermatitisSep 09
Almirall, S.A. Announces Topline Results from One-Year Analyses of the Efficacy and Safety of LebrikizumabJun 07
Almirall, S.A. Announces Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic DermatitisApr 12
Almirall launches innovative Wynzora® CAL/BDP cream in Europe for the treatment of mild to moderate plaque psoriasis in adults including scalpFeb 19
Almirall, S.A. Launches Klisyri (Tirbanibulin) for the Treatment of Actinic Keratosis in EuropeSep 29
Almirall and MC2 Therapeutics Announce Completion of Decentralized Procedure in Europe for the Topical Treatment of Mild to Moderate Psoriasis Vulgaris in AdultsJul 07
Almirall Receives Positive CHMP Opinion for Klisyri®? (Tirbanibulin), an Innovative Topical Treatment for Actinic KeratosisMay 22
Almirall U.S. Launches Klisyri® (tirbanibulin), a New, Innovative Topical Treatment for Actinic KeratosisFeb 19
Almirall and MC2 Therapeutics Enters a License, Collaboration and Commercialization Agreement for European Rights to Wynzora® Cream for treatment of Plaque PsoriasisFeb 18
Almirall and Happify Health Enter into Strategic Partnership to Develop Evidence-Supported Digital Therapeutics Solutions for Psoriasis PatientsJan 29
Almirall, S.A. and Tyris Therapeutics Enter into Strategic Partnership to Develop Next Generation Gene TherapiesJan 08
Almirall, S.A. Announces U.S. Food and Drug Administration Approval of Klisyri® (Tirbanibulin), A New Innovative Topical Treatment for Actinic KeratosisDec 15